中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (2): 98-102.doi: 10.12144/zgmfskin202502098

• 论著 • 上一篇    下一篇

口服普萘洛尔治疗81例高风险婴儿血管瘤疗效分析

张颖琦,韩建文,孙立,乌日嘎   

  1. 内蒙古医科大学附属医院皮肤科，内蒙古呼和浩特，010050
  • 出版日期:2025-02-15 发布日期:2025-01-22

Efficacy analysis of oral propranolol in the treatment of 81 cases with high-risk infantile hemangioma

ZHANG Yingqi, HAN Jianwen, SUN Li, WU Riga   

  1. Department of Dermatology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China
  • Online:2025-02-15 Published:2025-01-22

PDF (PC)

48

摘要： 目的：明确口服普萘洛尔治疗高风险婴儿血管瘤的有效性和安全性。方法：回顾性分析2018年3月至2024年1月收治的81例（96处皮损）口服普萘洛尔治疗的高风险婴儿血管瘤患儿的临床资料，评价治疗效果及安全性。结果：81例患儿首诊平均年龄3个月，普萘洛尔治疗6个月后96处血管瘤疗效:Ⅰ级12处，Ⅱ级12处，Ⅲ级20处，Ⅳ级52处，有效率 (Ⅲ级+Ⅳ级) 为75%。治疗起始年龄≤6个月的疗效优于治疗起始年龄＞6个月的疗效，差异有统计学意义(P＜0.05)；长疗程治疗效果优于短疗程，差异有统计学意义(P＜0.001)；不同部位婴儿血管瘤的治疗效果不存在差异(P＞0.05)。无明显严重不良反应发生且复发后给药仍然效果满意。结论：口服普萘洛尔治疗高风险婴儿血管瘤安全有效，患儿耐受性良好。

关键词: 婴儿血管瘤, 高风险, 普萘洛尔, 疗效

Abstract: Objective: To investigate the efficacy and safety of oral propranolol in the treatment of high-risk infantile hemangiomas. Methods: Retrospective analysis of the clinical data of 81 infants with high-risk hemangiomas treated with oral propranolol from March 2018 to January 2024, evaluating the treatment efficacy and safety. Results: The mean age of the first diagnosis of 81 children was 3 months, and the efficacy was evaluated after 6 months of treatment with propranolol. Efficacy of 96 hemangiomas in 81 patients were grade I of 12 lesions, grade II of 12 lesions, grade III of 20 lesions, grade IV of 52 lesions. The effective rate (grade III + grade IV) was 75%. The therapeutic effect of patients with the initial age of ≤6 months was better than that of patients with the initial age of > 6 months (P<0.05). The effect of long-term treatment was better than that of short-term treatment (P<0.001). However, there was no significant difference in the treatment effect of infantile hemangiomas in different locations (P>0.05). No obvious serious adverse reactions occurred and the treatment effect was still satisfactory after recurrence. Conclusion: Oral propranolol is safe, effective and well tolerated in the treatment of high-risk infantile hemangiomas.

Key words: infantile hemangioma, high-risk, propranolol, efficacy